Celgene Corp.

Meeting addressed progress and strategic direction for company’s induced mesenchymal stem cell (iMSC) therapy programs CAMBRIDGE, Mass., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Eterna Therapeutics (Nasdaq: ERNA), developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases, today announced a successful inaugural meeting of its newly formed Scientific Advisory Board. The meeting brought together leading experts in cell therapy to evaluate preclinical advances, address key scientific questions, refine the company’s research and development priorities, and discuss the roadmap to human clinical trials. The board consists of top leaders in the field, including: Michael Andreeff, MD, PhD, Professor in the Departments of Leukemia and Stem Cell Transplantation at The University of Texas MD Anderson Cancer Center Christopher Rohde, PhD, Co-founder and Chief Technology Officer of Factor Bioscience Blythe Sather, PhD, Vice President and Head of Research at Tune Therapeutics Jerome B. Zeldis, MD, PhD, held leadership roles at Celgene (now Bristol Myers Squibb) and NexImmune “The meeting was truly invigorating, sparking dynamic discussions and strategic brainstorming on advancing our next-generation cell therapies to bring the greatest benefit to people battling cancer and autoimmune disease,” said Sanjeev Luther, CEO of Eterna Therapeutics. “It was inspiring to witness the board’s unparalleled expertise, combined with their unwavering passion and commitment to driving innovation with the highest level of scientific rigor.” Some highlights from the meeting include: The board discussed the positive preclinical data for ERNA-101 in ovarian cancer, including immune activation, tumor microenvironment interactions, and potential combination strategies. Further studies are planned to optimize dose and route of administration in order to maximize downstream anti-tumor immune responses. The board was aligned on further advancing rigorous quality, safety, and efficacy criteria for product consistency, engaging with regulatory agencies, and prioritizing clinical trial design to accelerate the path to first-in-human studies. They also highlighted potential combination therapies with CAR-T therapy, MUC16-targeting agents, and other immunomodulatory approaches to enhance treatment efficacy in challenging disease areas. Lastly, the board focused on potential therapeutic indications within autoimmune disease for ERNA-102. Additional research will be conducted for further assessment. Eterna will continue to collaborate with the Scientific Advisory Board and key stakeholders to translate these innovative therapies into impactful clinical practice. About Eterna Therapeutics Eterna Therapeutics (Nasdaq: ERNA) is developing innovative cell therapies for the treatment of advanced solid tumors and autoimmune diseases. Eterna’s core technology focuses on engineering induced pluripotent stem cells (iPSCs) and transforming them into induced mesenchymal stem cells (iMSCs). Eterna’s allogeneic synthetic iMSCs provide a scalable, off-the-shelf treatment solution, without needing patient-specific cell harvesting. Eterna is developing two highly innovative stem cell therapy products, both currently in pre-clinical stages. ERNA-101 is the company’s lead cell therapy product, designed to activate and regulate the immune system's response to recognize and attack cancer cells. ERNA-102 is a cell therapy product designed to target inflammation and treat autoimmune disease. The company’s primary focus is to develop ERNA-101 for the treatment of ovarian cancer. For more information, visit www.eternatx.com. Forward-Looking Statements This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, which are intended to be covered by the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements, in some cases, can be identified by terms such as "believe," "may," "will," "estimate," "continue," "anticipate," "design," "intend," "expect," "could," "plan," "potential," "predict," "seek," "should," "would," "contemplate," "project," "target," "objective," or the negative version of these words and similar expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause Eterna's actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by the forward-looking statements in this press release, including, without limitation, risks and uncertainties related to: progress and possible outcomes of the Company’s lead research project, ERNA-101, and future research projects. Forward-looking statements are based upon Eterna's current expectations and involve assumptions that may never materialize or may prove to be incorrect. All forward-looking statements are expressly qualified in their entirety by these cautionary statements. For a detailed description of Eterna's risks and uncertainties, you are encouraged to review its documents filed with the SEC including its recent filings on Form 8-K, Form 10-K and Form 10-Q. You are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date on which they were made. Eterna does not undertake any obligation to update the forward-looking statements contained herein to reflect events that occur or circumstances that exist after the date hereof, except as required by applicable law. Media & Investor Relations Contact investors@eternatx.com

Adds three new directors with deep expertise across biopharma and life sciences Somerset, NJ – February 20, 2025 — Catalent, Inc., the leader in enabling the development and supply of better treatments for patients worldwide, today announced that it has appointed Susan Mahony, Marie-France Tschudin and Tim Walbert to its Board of Directors as the company continues its growth under Novo Holdings’ ownership. Alessandro Maselli, President and CEO, and Board member of Catalent, said “I am excited to work closely with these new Board members as we drive continued growth as an independent CDMO delivering unparalleled service to our pharma and biotech customers. Susan, Marie-France and Tim are each accomplished leaders who bring the right balance of industry experience and fresh perspective to achieve the vision for Catalent’s next chapter.” “We are thrilled to welcome these biopharma leaders to our Board, whose expertise in navigating the complexities of the healthcare landscape will be invaluable,” said John Greisch, Chair of the Board. “We look forward to benefitting from their insights in support of Catalent’s mission to develop, manufacture and supply products that help people live better and healthier lives.” The Catalent Board also includes Jonathan Levy, Senior Partner at Novo Holdings, and Charles Patten, Partner at Novo Holdings, both of whom joined the Board upon Catalent becoming a private company following the completion of the acquisition by Novo Holdings in December 2024. “On behalf of Novo Holdings, I am pleased to welcome our new Board members, said Jonathan Levy, Senior Partner, Novo Holdings. “Their diverse expertise and strategic insight will strengthen Catalent’s operations as an independent CDMO. We look forward to their contributions as we shape the company’s next chapter of growth and continued focus on improving the lives of patients worldwide.” The appointment of these new Board Directors is effective immediately and completes the Company’s updates to its Board, which is now comprised of 7 directors. Sue Mahony is a senior executive with over 30 years of experience in pharmaceutical and life sciences companies. Dr. Mahony served in a variety of senior leadership positions at Eli Lilly and Company from 2000 to 2018, most recently as Senior Vice President and President of Lilly Oncology and a member of the executive committee of Eli Lilly. Prior to joining Lilly, Dr. Mahony served in sales and marketing roles in Europe for over a decade for Schering-Plough, Amgen and Bristol Myers Squibb. She currently serves on the board of directors of Assembly Biosciences, Inc., Axsome Therapeutics, Inc. and Zymeworks, Inc., and she previously served on the board of directors of Horizon Therapeutics, plc and Vifor Pharma. Dr. Mahony received a BSc and a PhD from Aston University and an MBA from London Business School. Marie-France Tschudin is a global healthcare leader with 30 years of experience in the biotechnology and pharmaceutical industry. Until September 2023, Ms. Tschudin was President, Innovative Medicines International & Chief Commercial Officer of Novartis Pharma AG and a member of the Executive Committee. Before that, she held increasingly senior leadership positions, including President, Novartis Pharmaceuticals. Prior to joining Novartis, Ms. Tschudin spent 10 years at Celgene International in a variety of leadership positions across Europe. Ms. Tschudin started her career as a sales representative and then held a number of sales and marketing positions at Johnson & Johnson and Schering-Plough. Currently, she is a Board Director for AXA Group and Mars, Inc. Ms. Tschudin graduated with a Master of Business Administration from IMD business school in Switzerland, and a Bachelor of Science from Georgetown University. Tim Walbert served as the Chairman, President and Chief Executive Officer of Horizon Therapeutics from 2008 to October 2023, when it was acquired by Amgen for $28.3 billion. Before joining Horizon, he held various executive leadership positions across biotech and pharma companies, including at Abbott, now AbbVie, leading the global development and launch of the multi-indication biologic Humira. Mr. Walbert serves on the boards of directors of Century Therapeutics and Sagimet Biosciences, both public biotech companies, and Cour Pharmaceuticals, Odyssey Therapeutics and Latigo Therapeutics (chairman), each private clinical-stage biotech companies. Mr. Walbert received a Bachelor of Arts in Business from Muhlenberg College in Allentown, PA and now serves as a member of the College’s Board of Trustees. Catalent, Inc. is a leading global contract development and manufacturing organization (CDMO) whose mission is to develop, manufacture, and supply products that help people live better and healthier lives. Catalent is dedicated to delivering unparalleled service to pharma, biotech, and consumer health customers, supporting product development, launch, and full life-cycle supply. With time-tested experience in development sciences, delivery technologies, and multi-modality manufacturing, Catalent supports the acceleration of development programs and the launch of more than a hundred new products every year. Powered by thousands of scientists and technicians and the latest technology platforms at more than 40 global sites, Catalent supplies billions of doses of life-enhancing and life-saving treatments for patients annually. For more information, visit www.catalent.com. Media Contact: Laura Hortas +1(609) 240-7025 media@catalent.com

Dr Mozayeni brings deep experience in biotech corporate strategy and business development Appointment follows successful £35 million Series A fundraise at the end of 2024 to take its MSH3 inhibitors to treat Huntington's disease into the clinic CAMBRIDGE, England, Feb. 18, 2025 /PRNewswire/ -- LoQus23 Therapeutics Ltd ("LoQus23"), a private biotechnology company investigating small molecule drugs that could stop the pathogenic triplet expansion that is the cause and driver of Huntington's Disease, myotonic dystrophy type 1, and other triplet repeat expansion diseases, today announces the appointment of Dr Cyrus Mozayeni as its Chair of the Board of Directors. Dr Mozayeni is a highly experienced biotech entrepreneur with a track record of more than 20-years spearheading growth and strategic business development for life sciences companies. Dr Mozayeni is currently CEO of Pheon Therapeutics (Pheon), a leading antibody-drug conjugate (ADC) company developing next generation ADCs for a wide range of hard-to-treat cancers. He recently led Pheon through a successful $120 million Series B financing round in May 2024. Dr David Reynolds, Chief Executive Officer of LoQus23 Therapeutics, commented: "Following our successful fundraise late last year, the Company is at a pivotal moment as we progress towards IND-enabling studies of our potent allosteric small molecule MSH3 inhibitor, part of the MutSβ complex. Cyrus brings a wealth of world class biotech expertise to guide us at this critical time and will help us to deliver treatments for patients with Huntington's and similar triplet repeat expansion diseases." Dr Cyrus Mozayeni, newly appointed Chair of the Board of Directors of LoQus23, added: "The science behind LoQus23's unique approach is hugely promising. Several recent high-profile papers provide unequivocal support for the development of treatments targeting somatic CAG repeat expansion – the foundation of our approach. I look forward to working with the Board and the Leadership Team to help deliver the lead asset into the clinic and beyond." As an Entrepreneur-in-Residence at Atlas Venture, Dr Mozayeni launched Vedere Bio and served as President & CEO from inception through to its sale to Novartis. Before joining Atlas Venture, Dr Mozayeni was co-founder of CODA Biotherapeutics, and Oncorus, where he served as President and CBO. He also served as VP and Global Head of Business Development and Alliance Management at Nasdaq listed Bluebird Bio, where his efforts led to a clinical-stage CAR T-cell program (ABECMA®, idecabtagene vicleucel) in collaboration with Celgene, and a successful IPO. A qualified Doctor of Medicine, Dr Mozayeni is a graduate of the University of Virginia School of Medicine and holds both an MBA from the Kellogg School of Management of Northwestern University and an Sc.B. in Neuroscience from Brown University. In October 2024, LoQus23 announced the successful close of its £35 million Series A financing round led by Forbion, alongside existing investors SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. The Company has since established a platform of assays and small molecule series of MutSα and MutSβ inhibitors which are therapeutically relevant in numerous triplet repeat diseases, including Huntington's Disease. Notes to Editors About LoQus23 Therapeutics Ltd LoQus23 is a biotech company based in Cambridge, UK, developing small molecule somatic expansion inhibitors for the treatment of Huntington's Disease and other triplet repeat expansion diseases. Huntington's disease is an autosomal dominant neurodegenerative disorder for which there is currently no disease modifying treatment available and which currently has 30,000 patients in the US alone. LoQus23's approach has the potential to stop DNA instability and therefore slow neurodegeneration in these diseases. LoQus23 is focused on using a structure-based approach to design small molecule drugs, which can offer more convenient administration than other approaches. Oral small molecule drugs have a strong track record in treating complex brain diseases and provide greater convenience for patients compared with other advanced treatment modalities. LoQus23's lead programme, a potent allosteric small molecule MSH3 inhibitor, part of the MutSβ complex, will enter the clinic in 2026. LoQus23 has a highly experienced leadership team, built on world-class science. It was originally established in 2019 by Dr David Reynolds, Dr Caroline Benn, and Dr Ruth McKernan CBE, FMedSci, Entrepreneurs in Residence at SV Health Investors' Dementia Discovery Fund, which also acted as the initial seed investor. In October 2024, the Company closed a successful £35 million Series A financing round led by Forbion, alongside existing investors SV Health Investors' Dementia Discovery Fund and Novartis Venture Fund. For more information, please visit: SOURCE LoQus23 Therapeutics WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED